Document is current

Article History

Received: 2 December 2024

Accepted: 17 January 2025

First Online: 13 February 2025

Declarations

:

: Tavs Qvist discloses receiving compensation from Vertex Pharmaceuticals for lectures, presentations, speaking engagements, manuscript authorship, and educational events during the years 2021–2025, unrelated to the current work. Søren Jensen-Fangel declares receiving payment from GSK for delivering a lecture on pulmonary infections in immunocompromised hosts, unrelated to the submitted work, and serving on a Takeda advisory board in 2023, also outside submitted work. Vertex Pharmaceuticals funded this study and provided feedback on the manuscript prior to submission but did not influence the choice of study design, analysis, or interpretation of data. The final decisions regarding study methodology, data presentation, and manuscript content were made by the investigators. All other authors, including Hans Kristian Råket, Mikkel Zöllner Ankarfeldt, Joanna Nan Wang, Tacjana Pressler, Daniel Faurholt-Jepsen, Espen Jimenez-Solem, Janne Petersen, and Camilla Bjørn Jensen, report no other conflicts of interest.

: The project was approved by the Danish Data Protection Agency (ref. no. P-2020–1130). Data were stored in the DCFR with the individuals’ informed, written consent. We thank the individuals for their consent. All data were pseudonymized and accessed with permission from Statistics Denmark (project number FCVH708303). Ethical approval from the Danish Health Research Ethics Committee is not required for registry-based studies.